Group 1: Sanofi Pharmaceutical - Sanofi Pharmaceutical announced plans to spin off its subsidiary Mandi Holdings for independent listing on the Hong Kong Stock Exchange [1] - The proposed spin-off will involve a distribution of Mandi shares to existing shareholders based on their holdings in Sanofi [1] - Mandi Holdings is registered in the Cayman Islands and is currently owned by Sanofi and other entities, with Sanofi holding approximately 87.16% [1] Group 2: Yaoshi Bang - Yaoshi Bang reported a 15% year-on-year revenue growth for the third quarter ending September 30, 2025, surpassing the growth rate of the first half of 2025 compared to the same period in 2024 [2] - The company's self-owned brand business saw a transaction volume increase of over 350% year-on-year, contributing significantly to overall growth [2] - The strategic focus on self-owned brand products aims to meet diverse market demands and enhance profitability [2] Group 3: SenseTime Medical - SenseTime Medical completed a new round of strategic financing amounting to several hundred million yuan, with notable investors including Lenovo Ventures and others [3] - This financing reflects strong market recognition of SenseTime Medical's technological capabilities and growth potential [3] - The company is also initiating Series A financing with a post-investment valuation exceeding 3 billion yuan [3] Group 4: National Medical Products Administration - The National Medical Products Administration released a document outlining 24 reform measures to enhance the quality and safety of cosmetics [4] - The reforms aim to encourage innovation, optimize registration management, and strengthen risk prevention across the cosmetics industry [4] - By 2030, the goal is to have a more robust regulatory framework and improved safety standards in the cosmetics sector [4] Group 5: Hanyu Pharmaceutical - Hanyu Pharmaceutical announced the appointment of former senior executive Shen Yaping from Heng Rui Pharmaceutical as the new Executive President [5][6] - Shen Yaping has extensive experience in international business development and regulatory affairs in the pharmaceutical industry [6] - The company aims to adapt to a complex market environment through this strategic leadership change [6] Group 6: Meili Tianyuan Medical Health - Meili Tianyuan Medical Health plans to acquire 100% equity of several companies for a total consideration of 40 million yuan [7] - The acquisition will expand the company's direct-operated stores by 19, including two medical beauty stores and 17 lifestyle beauty stores [7] - This move is expected to enhance the company's revenue and strengthen its market presence in key cities in the Greater Bay Area [7]

Core Viewpoint - Han Yu Pharmaceutical has undergone significant management changes, appointing two new executive presidents to adapt to a complex market environment and pursue internationalization strategies [2][3][4]. Management Changes - The resignation of PINXIANG YU, the former executive president, was due to retirement, and he will not hold any positions in the company or its subsidiaries post-resignation [3]. - The board has appointed Tang Yangming and Shen Yaping as new executive presidents, with their terms lasting until the current board's term ends [3][4]. - Tang Yangming has over 20 years of experience in peptide drug research and has been with Han Yu Pharmaceutical since 2005 [3]. - Shen Yaping, an external hire, has a notable background in international business from his tenure at Jiangsu Hengrui Medicine Co., Ltd., where he held various senior roles [4]. Recent Personnel Adjustments - Han Yu Pharmaceutical has made multiple personnel adjustments in the second half of the year, affecting key positions such as vice presidents, board secretaries, and committee members [5][6]. - The company has seen a rapid succession of management changes, including the resignation of vice president Zhang Baole and board secretary Yang Di, both of whom left for personal reasons [6]. Financial Performance - In the first three quarters of the year, Han Yu Pharmaceutical reported a revenue of 683 million yuan, marking an 82.06% year-on-year increase, and a net profit of 71.35 million yuan, indicating a turnaround from losses [7]. - The company achieved an operating cash flow of 271 million yuan, a significant increase of 207.37%, setting a historical high for the same period [7].

Group 1 - The core viewpoint of the article highlights the recent management restructuring at Hanyu Pharmaceutical, indicating a shift towards a dual CEO structure with both external and internal leadership to enhance operational efficiency [2][4][6] Group 2 - The management changes began in August 2025 with the resignation of the Vice President responsible for overseas marketing, followed by further adjustments in October and November, indicating a trend of personnel turnover across key operational areas [4][6] - The adjustments cover critical management aspects including market expansion, capital market communication, and overall company operations, suggesting a comprehensive overhaul of the management structure within a short timeframe [6]

Core Insights - Shenzhen Hanyu Pharmaceutical Co., Ltd. has appointed Tang Yangming and Shen Yaping as executive presidents to enhance management structure and achieve complementary advantages [1][2] Group 1: Management Changes - Tang Yangming has over 20 years of experience in peptide drug research and has been a senior vice president at Hanyu Pharmaceutical, ensuring effective execution of company strategies [1] - Shen Yaping brings extensive experience from his tenure at Hengrui Medicine, focusing on international market strategies and commercialization, which aligns with Hanyu Pharmaceutical's expansion into overseas markets [1][2] Group 2: Strategic Implications - The addition of Shen Yaping is expected to infuse Hanyu Pharmaceutical with innovative drug development strategies, particularly in peptide drugs, enhancing clinical progression and commercialization efforts [2] - Tang Yangming's promotion reflects the company's commitment to internal talent development, ensuring continuity in core technologies and stable operations [2]

Core Viewpoint - Han Yu Pharmaceutical announced the nomination of Mr. Shen Yaping as a candidate for the sixth non-independent director [2] Group 1 - The company intends to supplement its board with a new non-independent director [2]

Core Viewpoint - The announcement from Hanyu Pharmaceutical indicates that the company's Executive Director and CEO, Pinxiang Yu, has submitted her retirement application due to reaching the retirement age, effective immediately upon delivery to the board [2]. Group 1 - Pinxiang Yu will resign from her positions as both Executive Director and CEO of Hanyu Pharmaceutical, with her term originally set to last until the end of the sixth board's term [2]. - After her resignation, Pinxiang Yu will no longer hold any positions within the company or its subsidiaries [2].

Core Viewpoint - Han Yu Pharmaceutical (300199) announced the appointment of Tang Yangming and Shen Yaping as the company's executive presidents [1] Group 1 - The board of directors approved the hiring of Tang Yangming as executive president [1] - The board of directors approved the hiring of Shen Yaping as executive president [1]

Group 1 - The core point of the news is the retirement of Ms. Pinxiang Yu, the director and CEO of Hanyu Pharmaceutical, effective November 14, 2025, due to reaching retirement age [1] - After her retirement, Ms. Pinxiang Yu will no longer hold any positions within the company or its subsidiaries [1] - For the first half of 2025, Hanyu Pharmaceutical's revenue is entirely derived from the pharmaceutical manufacturing sector, accounting for 100% of its business [1] Group 2 - As of the report, Hanyu Pharmaceutical has a market capitalization of 17.1 billion yuan [2]

Group 1 - The core point of the article is that Hanyu Pharmaceutical (SZ 300199) held its 10th meeting of the 6th Board of Directors on November 17, 2025, to review various documents, including a proposal to amend the "Annual Work System of the Board Audit Committee" [1] - For the first half of 2025, Hanyu Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the time of reporting, Hanyu Pharmaceutical has a market capitalization of 17.1 billion yuan [2]

深圳翰宇药业股份有限公司 财务管理制度 第一章 总则 第一条 为规范深圳翰宇药业股份有限公司（以下简称"公司"）财务管理工 作，加强公司的财务监督，维护公司、投资者及其他相关方的合法权益，保护资产 的安全、完整，使财务管理工作有法可依、有章可循，根据《中华人民共和国公司 法》《中华人民共和国会计法》《企业会计准则》《会计基础工作规范》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》及《公司章程》等，结合公司具体情况，制定本制度。 第二条 本制度是公司财务管理工作的基本制度，公司应根据本制度及国家相 关法规、准则的规定，结合实际情况，建立、健全各项基础财务工作制度，做好财 务管理基础工作，如实反映公司财务状况，依法计算和缴纳国家税收；审慎经营， 有效防范和化解资产损失风险，为经营活动提供决策支持；并真实、准确、完整、 及时和公平地进行信息披露，保障投资者权益。 第三条 公司财务行为和财务管理工作必须遵守国家有关法律法规，并接受政 府有关部门、公司董事会、审计委员会和合规管理部的检查和监督。 第二章 财务组织体系 第四条 财务机构设置和人员配备 1 ...